Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $69.91M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.24M
Average 19.76M
GOSS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Gossamer Bio, Inc.NASDAQ: GOSS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $46.66M (cash outflow) rose 27.4% year over year, behind the +252.1% change in trailing-twelve-month net income. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at -9.4% a year.
Context
- Net income amounted to 351.5% of revenue in FY2025, up 302.2 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$93.3M (-45.2%) for the fiscal year ending Dec 2026, a slowdown from the +201.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$46.66M-1.2% QoQ
- Last fiscal yearDec 2025
- -$170.37M+201.4% YoY
- LTMMar 2026
- -$180.4M+252.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.4% | +68.5% | +41.1 pp |
| 1 year | +201.4% | -45.2% | -246.6 pp |
| 3-year CAGR | -9.4% | -58.1% | -48.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (170.37M) USD
- Year-over-year change
- -201.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (170.37M) | -201.4% |
| FY2024 | 2024-12-31 | (56.53M) | +68.6% |
| FY2023 | 2023-12-31 | (179.82M) | +21.6% |
| FY2022 | 2022-12-31 | (229.38M) | +2.0% |
| FY2021 | 2021-12-31 | (234M) | — |
Net Income vs competitors
How GOSS compares with its peers on the latest reported figures
- GOSS's LTM Mar 2026 net income of $180.4M is the 4th largest of the 9 companies compared; the peer median is $144.81M.
- Its year-over-year change of +252.1% is the 2nd highest of 8, against a peer median of +37.1%.
- Net income amounts to 324.8% of revenue for GOSS, versus a peer median of 151.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $364.23M | +879.7% | — | 121.5% | |
| LTM Mar 2026 | $290.01M | +83.9% | -11.6% | 330.2% | |
| LTM Mar 2026 | $185.15M | +43.6% | +15.7% | — | |
| LTM Mar 2026 | $180.4M | +252.1% | -9.4% | 324.8% | |
| LTM Mar 2026 | $160.9M | -8.8% | +9.2% | 182.3% | |
| LTM Mar 2026 | $151.18M | +37.1% | +27.8% | 260.9% | |
| LTM Dec 2025 | $138.44M | — | — | 119.4% | |
| LTM Mar 2026 | $44.17M | +6.7% | -28.2% | — | |
| LTM Mar 2026 | $26.09M | -85.3% | -21.0% | 37.5% | |
| Peer median (excluding GOSS) | $144.81M | +37.1% | -1.2% | 151.9% | |
Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (234M) | (229.38M) | (179.82M) | (56.53M) | (170.37M) |
| Depreciation & Amortization | 5.17M | 4.43M | 4.39M | 4.15M | 1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 32.01M | 42.55M | 28.52M | 20.62M | 10.56M |
| Change in Working Capital | 774K | (4.46M) | (14.84M) | 39.46M | (13.63M) |
| Accounts Receivables | 0 | 0 | 0 | (5.34M) | (6.89M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.43M) | (1.81M) | 3.99M | (1.66M) | (2.75M) |
| Other Working Capital | 5.2M | (2.65M) | (18.83M) | 46.45M | (3.99M) |
| Other Non-Cash Items | 7.17M | (177K) | 2.6M | (11.17M) | 1.18M |
| Operating Cash Flow | (188.89M) | (187.03M) | (159.16M) | (3.47M) | (171.27M) |
| Capital Expenditures | (1.62M) | (475K) | 0 | 0 | (79K) |
| Acquisitions (Net) | 0 | (65K) | 0 | 0 | 0 |
| Purchases of Investments | (152.03M) | (238.06M) | (441.67M) | (494.78M) | (227.11M) |
| Sales of Investments | 36.23M | 237.5M | 330.7M | 523.8M | 383.54M |
| Other Investing Activities | (75K) | 65K | 0 | 0 | 0 |
| Investing Cash Flow | (117.43M) | (1.04M) | (110.97M) | 29.02M | 156.36M |
| Debt Repayment | 0 | (5.81M) | (11.61M) | (12.58M) | 0 |
| Common Stock Issued | 0 | 119.95M | 201.32M | 464K | 6.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 629K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.33M | 2.95M | 444K | 0 | 0 |
| Financing Cash Flow | 3.33M | 117.09M | 190.15M | (11.49M) | 6.43M |
| Effect of Forex Changes | (165K) | (517K) | 110K | (102K) | 141K |
| Net Change in Cash | (303.15M) | (71.49M) | (79.86M) | 13.97M | (8.34M) |
| Free Cash Flow | (190.51M) | (187.51M) | (159.16M) | (3.47M) | (171.35M) |
Gossamer Bio, Inc.
NASDAQ:GOSS
Intrinsic Alpha fair value
Locked
Current Price
$11.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.